Chimerigen

CD152 [CTLA-4] (mouse):Fc (mouse) (rec.) (non-lytic)

CHF 130.00
In stock
CHI-MF-120A4-C100100 µgCHF 130.00
CHI-MF-120A4-C500500 µgCHF 370.00
More Information
Product Details
Synonyms CTLA-4
Product Type Protein
Properties
Source/Host NS1 cells
Sequence

The extracellular domain of mouse CD152 [CTLA-4] (aa 1-160) is fused to the N-terminus of the Fc region of a mutant mouse IgG2a.

Crossreactivity Mouse
Biological Activity

Blocks the binding of mouse CD80 (B7-1) and CD86 (B7-2) to their receptors (by binding CD80 and CD86 with high affinity) and thereby prevents their T cell regulatory actions by inhibiting the CD28 signaling competitively. Shows the biological functions of the CD152 moiety and exerts a prolonged circulating half-life caused by the modified Fc domain. Useful for investigating the T cell co-stimulation.

Purity ≥98% (SDS-PAGE)
Endotoxin Content <1EU/mg protein (LAL test; Lonza).
Reconstitution Reconstitute at 100μg/ml in sterile PBS.
Formulation Lyophilized from 0.2μm-filtered solution in PBS.
Protein Negative Control

Fc (mouse) IgG2a Control (rec.) (non-lytic)

Other Product Data

Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).

NCBI reference NP_033973.2: CD152 (mouse)

Declaration Manufactured by Chimerigen.
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

CD152 [CTLA-4] and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD152 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD152 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD152 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. CD152 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CD152 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CD152 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CD152 and CD28 can bind to the same ligands, CD152 binds to B71 and B72 with 20-100-fold higher affinity than CD28.

Product References
  1. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance: W. Steurer, et al.; J. Immunol. 155, 1165 (1995)
  2. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice : E.A. Tivol, et al.; J. Immunol. 158, 5091 (1997)
  3. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation: J.A. Gonzalo, et al.; J. Immunol. 166, 1 (2001)
  4. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease: S. Paust, et al.; PNAS 101, 10398 (2004)
  5. Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes: S. Eventov-Friedman, et al.; PLoS Med. 3, e215 (2006)
  6. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses: M.J. Butte, et al.; Immunity 27, 111 (2007)
  7. Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes: D. Tchorsh-Yutsis, et al.; Diabetes 58, 1585 (2009)
  8. Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA-4-Dependent Manner: T. Zhang, et al.; Am. J. Transplant. 11, 1599 (2011)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.